Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Net Cash Flow: 2019-2025

Historic Net Cash Flow for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -$106.0 million.

  • BridgeBio Pharma's Net Cash Flow rose 25.16% to -$106.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $237.2 million, marking a year-over-year increase of 304.04%. This contributed to the annual value of $288.5 million for FY2024, which is 1402.42% up from last year.
  • BridgeBio Pharma's Net Cash Flow amounted to -$106.0 million in Q3 2025, which was down 150.88% from $208.4 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Net Cash Flow peaked at $275.4 million during Q4 2024, and registered a low of -$198.0 million during Q3 2021.
  • Over the past 3 years, BridgeBio Pharma's median Net Cash Flow value was $18.2 million (recorded in 2023), while the average stood at $20.7 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 2,548.19% in 2021, then plummeted by 269.76% in 2025.
  • Over the past 5 years, BridgeBio Pharma's Net Cash Flow (Quarterly) stood at $213.3 million in 2021, then slumped by 132.30% to -$68.9 million in 2022, then plummeted by 87.82% to -$129.4 million in 2023, then surged by 312.79% to $275.4 million in 2024, then increased by 25.16% to -$106.0 million in 2025.
  • Its last three reported values are -$106.0 million in Q3 2025, $208.4 million for Q2 2025, and -$140.5 million during Q1 2025.